Clay is the co- founder of Seattle Genetics, Inc. It was founded in 1997 and since 2000 he has been its CEO. Dr. Clay’s close to 20 years of cancer research experience as well as therapeutic drug creation has put him ahead with other authorities in medicine and science.
From December of 1997, he served as the Executive VP of Seattle Genetics Inc. He also served as the company’s chief scientific officer until 2002. Prior to founding this company, Dr. Clay worked with Bristol-Myers Pharmaceutical Institute as a research investigator in a senior capacity from 1991 to January 1995. He was promoted to principal scientist from 1995 to December of 1997.
Clay Siegall has served as chairman at Seattle Genetics, Inc since 2004. He has been interim chairman since early 2004. At Ultrgenyx pharmaceutical, he occupies the position of director since 2014. He is the director at Washington Biotechnology and Biomedical Association (WBBA). He also sits on Fred Hutchinson Cancer Research Business Alliance board of governors. At Mirna Therapeutics, he served as a non-executive director from early 2013 to 2017.
Writing and Awards
Clay has 67 scientific papers to his credit. He has nine patent rights. He is on three scientific journals’ editorial boards. He is a member of the Cancer Treatment Research Foundation’s scientific counselor’s board. In 1995 he was awarded the Pierce Aaward for his contribution in the targeted toxins field. A few years later, in 2002, he was Ernst and Young’s Pacific Northwest Entrepreneur of the year finalist.
In one of the recent posts on Dr. Siegall’s post, the negative effects of solitary confinement are highlighted. It is argued by the author that the prisoners soon crave the touch of a fellow person and communion. They lose track of the days and nights and are not sure of the days or months any more. The negative effects of this confinement have become a cause for debate in recent years.
In another post, US military is trying to determine whether the troops who handle heavy firing machines are at risk of brain damage when they fire them. The hot gases the machines emit upon firing are a question for speculative debate.
Cancer is among diseases that have been giving professionals from all areas of medicine hard time while looking for solutions that could lead to better methods of dealing with the disease. It has been allotted a lot of money and experts spend time looking for ideas that could lead to solutions in dealing with the menace.
The development of cancer institutes has allowed the growth of research methods that have led to the discovery of effective treatment methods. Seattle Genetics is among biotechnology companies that have worked on delivering better healthcare to the people. Under the leadership of Clay Siegall, the company came up with new methods of dealing with cancer that are more effective.
Clay Siegall is a professional who has through his entire career worked on developing better healthcare systems and his focus all along has remained on cancer treatment. With the effort he has put to research, Clay Siegall has managed to steer Seattle Genetics well to allow the company to explore new and better ways of delivering treatment to patients. Clay Siegall is a professional whose career as a researcher has revealed many solutions in the fight against cancer and his most notable achievement came when he launched ADCETRIS, a revolutionary drug that helps in the treatment of cancer and related ailments.
Research for effective cancer treatment
Additionally, Clay Siegall has worked to ensure Seattle Genetics enters into partnerships with leading biotechnology companies like GlaxoSmithKline and Abbvie. These partnerships are built around research and working together to deliver solutions for the development of cancer treatment methods. So many achievements have come along through these research projects and one of them was the development of the ADC Technology that offers better methods of resolving problems related to cancer.
Growing to become an internationally recognized company took Seattle Genetics a lot of sacrifice and effort and their CEO, Clay Siegal was a key pillar in the development of the company. Since inception in 1998, the company has narrowed its operations to research and the development of new methods of treating diseases. Clay Siegall appreciates the progress the company has made over the years while fighting cancer.